Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction
September 06, 2022 08:00 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative...
Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 16:01 ET
|
Tenaya Therapeutics, Inc.
Received State Licensing to Enable cGMP Manufacturing of Drug Product TN-201 and TN-301 IND Submissions on Track for Second Half 2022 Presented Preclinical Data for Multiple Pipeline Programs and...
Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure
July 06, 2022 14:00 ET
|
Tenaya Therapeutics, Inc.
Tenaya’s Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms Tenaya’s HDAC6 Inhibitor TN-301 Advancing to the Clinic for HFpEF, with...